UA66932C2 - Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine - Google Patents

Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine

Info

Publication number
UA66932C2
UA66932C2 UA2001129200A UA2001129200A UA66932C2 UA 66932 C2 UA66932 C2 UA 66932C2 UA 2001129200 A UA2001129200 A UA 2001129200A UA 2001129200 A UA2001129200 A UA 2001129200A UA 66932 C2 UA66932 C2 UA 66932C2
Authority
UA
Ukraine
Prior art keywords
complex
sulphobutylether
eletriptan
cyclodextrin
beta
Prior art date
Application number
UA2001129200A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UA66932C2 publication Critical patent/UA66932C2/xx

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UA2001129200A 1999-06-29 2000-06-02 Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine UA66932C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9915231.6A GB9915231D0 (en) 1999-06-29 1999-06-29 Pharmaceutical complex
PCT/IB2000/000746 WO2001000243A1 (en) 1999-06-29 2000-06-02 Pharmaceutical complex

Publications (1)

Publication Number Publication Date
UA66932C2 true UA66932C2 (en) 2004-06-15

Family

ID=10856302

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2001129200A UA66932C2 (en) 1999-06-29 2000-06-02 Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine

Country Status (44)

Country Link
US (2) US6713461B1 (is)
EP (1) EP1189640B1 (is)
JP (2) JP4454900B2 (is)
KR (1) KR20020015067A (is)
CN (1) CN1198654C (is)
AP (1) AP2001002369A0 (is)
AR (1) AR033337A1 (is)
AT (1) ATE290884T1 (is)
AU (1) AU770169B2 (is)
BG (1) BG106151A (is)
BR (1) BR0011845A (is)
CA (1) CA2376847C (is)
CO (1) CO5170494A1 (is)
CZ (1) CZ20014572A3 (is)
DE (1) DE60018744T2 (is)
DZ (1) DZ3320A1 (is)
EA (1) EA003908B1 (is)
EC (1) ECSP003551A (is)
EE (1) EE200100697A (is)
ES (1) ES2235879T3 (is)
GB (1) GB9915231D0 (is)
GE (1) GEP20043377B (is)
GT (1) GT200000102A (is)
HR (1) HRP20010951A2 (is)
HU (1) HUP0201629A3 (is)
IL (1) IL146341A0 (is)
IS (1) IS6163A (is)
MA (1) MA26801A1 (is)
MX (1) MXPA01013274A (is)
NO (1) NO20016430L (is)
NZ (1) NZ515235A (is)
OA (1) OA11964A (is)
PA (1) PA8496801A1 (is)
PE (1) PE20010346A1 (is)
PL (1) PL352902A1 (is)
SK (1) SK18932001A3 (is)
SV (1) SV2002000112A (is)
TN (1) TNSN00142A1 (is)
TR (1) TR200103827T2 (is)
UA (1) UA66932C2 (is)
UY (1) UY26224A1 (is)
WO (1) WO2001000243A1 (is)
YU (1) YU87501A (is)
ZA (1) ZA200110454B (is)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
SI1542668T1 (sl) 2002-08-20 2009-08-31 Bristol Myers Squibb Co Aripiprazol sestavljena formulacija in postopek
GB0329918D0 (en) * 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
CN1296391C (zh) * 2004-03-04 2007-01-24 中国人民解放军第二军医大学 氟代羧烷基环糊精醚类化合物及其制备方法和应用
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
CN101957330B (zh) * 2010-06-12 2013-10-09 南京巨环医药科技开发有限公司 磺丁基倍他环糊精含量的测定方法
WO2017122161A1 (en) * 2016-01-15 2017-07-20 Cadila Healthcare Limited An intranasal composition comprising 5ht1b/1d receptor agonists
US20190224171A1 (en) * 2018-01-22 2019-07-25 Insys Development Company, Inc. Liquid rizatriptan compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
HU211648A9 (en) 1990-03-28 1995-12-28 Chinoin Gyogyszer Es Vegyeszet Inclusion complexes of 3-morpholino-sydnonimine or its salts or its tautomer isomer, process for the preparation thereof, and pharmaceutical compositions containing the same
HU210921B (en) 1990-03-28 1995-09-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them
RU2095360C1 (ru) 1990-10-15 1997-11-10 Пфайзер Инк. Производные индола, их оптические изомеры и фармацевтически приемлемые соли
RU2143896C1 (ru) 1993-03-05 2000-01-10 Хексаль Аг Кристаллический комплекс циклодекстрина с гидрохлоридом ранитидина, способ его получения и содержащие его фармацевтические составы
JPH08510761A (ja) 1994-03-07 1996-11-12 ザ・ダウ・ケミカル・カンパニー 生物活性及び／又はターゲテッドデンドリマー複合体
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
WO1998002186A1 (en) 1996-07-11 1998-01-22 Farmarc Nederland B.V. Inclusion complex containing indole selective serotonin agonist
US5998462A (en) 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
GB9704498D0 (en) 1997-03-05 1997-04-23 Glaxo Wellcome Spa Chemical compound
PL337803A1 (en) 1997-07-03 2000-09-11 Pfizer Pharmaceutic agents containing eletriptane hemisulphate and caffeine
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex

Also Published As

Publication number Publication date
EP1189640B1 (en) 2005-03-16
EA003908B1 (ru) 2003-10-30
NZ515235A (en) 2003-08-29
WO2001000243A1 (en) 2001-01-04
BR0011845A (pt) 2002-03-05
PA8496801A1 (es) 2002-02-21
IL146341A0 (en) 2002-07-25
UY26224A1 (es) 2001-01-31
SK18932001A3 (sk) 2002-09-10
CZ20014572A3 (cs) 2002-08-14
AP2001002369A0 (en) 2001-12-31
IS6163A (is) 2001-11-16
CA2376847C (en) 2007-09-25
TR200103827T2 (tr) 2002-05-21
CO5170494A1 (es) 2002-06-27
MXPA01013274A (es) 2002-06-04
CN1359303A (zh) 2002-07-17
JP2003503364A (ja) 2003-01-28
US20040186076A1 (en) 2004-09-23
EA200101106A1 (ru) 2002-06-27
AU4774100A (en) 2001-01-31
CN1198654C (zh) 2005-04-27
AU770169B2 (en) 2004-02-12
HRP20010951A2 (en) 2005-04-30
SV2002000112A (es) 2002-02-05
PE20010346A1 (es) 2001-03-26
ATE290884T1 (de) 2005-04-15
GEP20043377B (en) 2004-04-13
TNSN00142A1 (fr) 2005-11-10
DZ3320A1 (fr) 2001-01-04
PL352902A1 (en) 2003-09-22
ECSP003551A (es) 2002-01-25
DE60018744T2 (de) 2006-05-18
YU87501A (sh) 2004-05-12
EE200100697A (et) 2003-02-17
GT200000102A (es) 2001-12-14
JP2006257091A (ja) 2006-09-28
AR033337A1 (es) 2003-12-17
BG106151A (en) 2002-05-31
JP4454900B2 (ja) 2010-04-21
EP1189640A1 (en) 2002-03-27
ES2235879T3 (es) 2005-07-16
HUP0201629A3 (en) 2003-11-28
US6713461B1 (en) 2004-03-30
OA11964A (en) 2006-04-17
MA26801A1 (fr) 2004-12-20
NO20016430D0 (no) 2001-12-28
NO20016430L (no) 2002-02-26
HUP0201629A2 (hu) 2003-03-28
KR20020015067A (ko) 2002-02-27
GB9915231D0 (en) 1999-09-01
DE60018744D1 (de) 2005-04-21
CA2376847A1 (en) 2001-01-04
ZA200110454B (en) 2002-12-20

Similar Documents

Publication Publication Date Title
HK1056683A1 (en) New pharmaceutical composition
PT991653E (pt) Novos compostos
IL145429A0 (en) N-cyanomethyl amides, processes for the preparation thereof and pharmaceutical compositions containing the same
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
EP1024145A3 (en) Novel azalides and methods of making same
MXPA03007837A (es) Composiciones para suministrar bisfosfonatos.
BG105459A (en) Pharmaceutical moxifloxacin preparation
PL367682A1 (en) Dolastatin 10 derivatives
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
AU6469401A (en) Pharmaceutically active compounds and methods of use
MXPA03009984A (es) PREPARACION PARA LA REMOCIoN DE MATERIAL QUERATINOSO ANORMAL.
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
GB9907571D0 (en) Compounds
HK1060558A1 (en) 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof.
GEP20063719B (en) Prevention of Migraine Recurrence
CA2296560A1 (en) Amino acid derivatives useful to treat stroke
DE69917005D1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
BG105204A (en) Salts of paroxetine
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
EP1303300A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANDIDIASIS
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
WO2002076930A3 (en) Substituted diarylureas as stimulators for fas-mediated apoptosis